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Abstract
Background: Low body mass index has been associated with increased mortality in
severe COPD. The impact of body composition earlier in the disease remains unclear.
We studied the impact of body composition on the risk of functional limitation in
COPD.
Methods: We used bioelectrical impedance to estimate body composition in a cohort
of 355 younger adults with COPD who had a broad spectrum of severity.
Results: Among women, a higher lean-to-fat ratio was associated with a lower risk of
self-reported functional limitation after controlling for age, height, pulmonary function
impairment, race, education, and smoking history (OR 0.45 per 0.50 increment in lean-
to-fat ratio; 95% CI 0.28 to 0.74). Among men, a higher lean-to-fat ratio was associated
with a greater distance walked in 6 minutes (mean difference 40 meters per 0.50 ratio
increment; 95% CI 9 to 71 meters). In women, the lean-to-fat ratio was associated with
an even greater distance walked (mean difference 162 meters per 0.50 increment; 95%
CI 97 to 228 meters). In women, higher lean-to-fat ratio was also associated with better
Short Physical Performance Battery Scores. In further analysis, the accumulation of
greater fat mass, and not the loss of lean mass, was most strongly associated with
functional limitation among both sexes.
Conclusion:  Body composition is an important non-pulmonary impairment that
modulates the risk of functional limitation in COPD, even after taking pulmonary
function into account. Body composition abnormalities may represent an important
area for screening and preventive intervention in COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is a com-
mon chronic health condition, affecting 5–10% of the
U.S. population [1,2]. Disability from COPD is substan-
tial, and will likely increase in the U.S. and worldwide
[3,4]. Despite these trends, the current understanding of
how disability develops in COPD is limited. Although
pulmonary function is the most important indicator of
physiologic impairment in COPD [5,6], it is a paradoxi-
cally a weak predictor of functional limitations [7-9].
Functional limitations, which are decrements in basic
physical actions (e.g., mobility, strength), are the key pre-
cursors to disability [10,11]. To elucidate the pathway to
disability in COPD, we must first understand which phys-
iological impairments, beyond pulmonary function, are
important contributors to functional limitation.
An emerging literature suggests that body composition
abnormality, especially low body mass index and fat free
mass, are an important non-pulmonary physiologic
impairment in COPD [12]. In particular, low body mass
index or depletion of fat free mass has been associated
with increased mortality, lower maximal exercise per-
formance, and poorer health-related quality of life [13-
22]. Most of these studies, however, have recruited
patients with severe lung disease, oftentimes from pulmo-
nary rehabilitation programs. Consequently, the impact
of body composition earlier in the disease, when preven-
tion of functional limitation and disability may still be
possible, is less clear. Supporting the possible role of body
composition earlier in the disease course, Vestbo and col-
leagues recently found that low fat free mass and body
mass index predicted a higher mortality among patients
who had predominately early stage disease [23]. Another
study of ambulatory patients with COPD found a rela-
tionship between low fat free mass and lower handgrip
strength, but there were no differences in dyspnea or
health-related quality of life [24]. In the current study, we
evaluated the association between body composition and
the risk of functional limitation among patients with a
broad range of COPD severity recruited from an inte-
grated health care delivery system in Northern California.
The goal of this analysis was to study body composition
in patients with COPD at a point at which clinical inter-
vention and disability prevention may still be possible.
Methods
Overview
The FLOW study of COPD (Function, Living, Outcomes,
and Work) is an ongoing prospective cohort study of adult
members of a closed panel managed care organization
with physician's diagnosis of COPD. Its long-term goal is
to determine what factors are responsible for the develop-
ment of disability in COPD. At baseline assessment, we
conducted structured telephone interviews that ascer-
tained COPD status, health status, health-related quality
of life, self-reported functional limitations, and sociode-
mographic characteristics. Subjects then underwent a
research clinic visit that included spirometry, bioelectrical
impedance, and other physical assessments. Using these
baseline data, we evaluated the cross-sectional impact of
body composition on the risk of functional limitations
among adults with COPD. The study was approved by the
University of California, San Francisco Committee on
Human Research and the Kaiser Foundation Research
Institute's institutional review board.
Subject recruitment
We studied adult members of Kaiser Permanente (KP), the
nation's largest non-profit managed care organization. In
Northern California, the Kaiser Permanente Medical Care
Program (KPMCP) provides the full spectrum of primary-
to-tertiary care to approximately 3.1 million members. In
Northern California, KP's share of the regional population
ranges from 25 to 30% [25]. The demographic character-
istics of KP membership are similar to the overall North-
ern California population, except for the extremes of
income distribution [26].
We identified all adult KPMCP members aged 40–65
years who were recently treated for COPD using a previ-
ously described approach [27]. Because an overall study
outcome is work disability, younger adults with COPD
were recruited. Using KPMCP computerized databases, we
identified all subjects who had health care utilization for
COPD during the most recent 12 month time period,
including 1 or more ambulatory visits, emergency depart-
ment visits, or hospitalizations with a principal Interna-
tional Classification of Disease (ICD-9) diagnosis code for
COPD, which included chronic bronchitis (491), emphy-
sema (492), or COPD (496) PLUS two or more prescrip-
tions for a COPD-related medication during a 12 month
window beginning 6 months before the index utilization
date and ending 6 months after index date (these medica-
tions included inhaled anticholinergic medications,
inhaled beta agonists, inhaled corticosteroids, and theo-
phylline). Based on medical record review, we demon-
strated that this algorithm is a valid method for
identifying adults with COPD [27]. To facilitate attend-
ance at the research clinic, we restricted the sample to per-
sons living within a 30 mile radius of the clinic. The
primary care physician for each patient was contacted and
given the opportunity to decline contact of their patients.
Potential subjects were then contacted by a letter describ-
ing the study and given the opportunity to decline by
mail. Those not declining were then contacted by tele-
phone to arrange an interview. At the end of the interview,
subjects were invited to participate in the research clinic
visit. Persons who were found to have other severe life-
threatening conditions (e.g., cancer), severe communica-Respiratory Research 2007, 8:7 http://respiratory-research.com/content/8/1/7
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tion or language difficulties (e.g, dementia or stroke), or
were not proficient in English were excluded.
This analysis was conducted after the first phase of cohort
recruitment. 3144 subjects with COPD were identified
and the first randomly sampled 1183 subjects who met all
study criteria were eligible for the current analysis. Of the
1183 eligible subjects, 710 (60%) subjects completed
structured telephone interviews and 355 (50%) com-
pleted the research clinic visit.
Structured telephone interviews
Each subject underwent a structured telephone interview
that was 30–40 minutes in length and conducted using
customized computer-assisted telephone interview soft-
ware. Interviews ascertained age, sex, race-ethnicity, and
educational attainment. Cigarette smoking was measured
using questions developed for the National Health Inter-
view Survey [28]. As in previous studies, we defined edu-
cational attainment as high school or less, some college,
or college/graduate degree [4]. Race-ethnicity was catego-
rized as previously described [4].
Self-reported functional limitation was measured using a
previously validated approach used by Sternfeld and col-
leagues, based on questions from the Framingham Disa-
bility Study, Established Populations for Epidemiologic
Studies of the Elderly, the Nagle scale, and Rosow and Bre-
slau scales [29]. The scale is comprised of 10 questions
that assess the degree of difficulty in multiple domains of
basic physical functioning such as pushing, stooping,
kneeling, getting up from a standing position, lifting
lighter or heavier objects, standing, sitting, standing from
a seated position, walking up stairs, and walking in the
neighborhood. Subjects who indicated "a lot of difficulty"
with one or more functions or not doing a function
because they were unable or they were told by a doctor not
to were defined as having a self-reported functional limi-
tation [29].
Assessment of body composition and size
Body composition was assessed using bioelectric imped-
ance (BIA).The Quantum II Bioelectrical Body Composi-
tion Analyzer (RJL Systems, Clinton Township, MI) was
used. While subjects were lying supine, we applied bipolar
electrodes on the middle finger of the right hand and the
lateral aspect of the right ankle to obtain measures of
resistance and reactance. To calculate lean and fat mass,
we used established sex-specific regression equations
derived from healthy adults living in Northern California
who underwent both BIA testing with the Quantum II
device and whole-body dual energy x-ray absorptiometry
(DEXA) scans [29]. Lean mass and lean-plus-bone mass
were derived from these regression equations (in kilo-
grams); fat mass was obtained by subtracting lean-plus-
bone mass from weight (because weight = fat mass + lean-
plus-bone mass) [29].
A relative measure of body composition, the lean-to-fat
ratio, was calculated by dividing lean mass by fat mass.
Previous work has established that lean-to-fat ratio is
more closely related to functional limitation than lean
mass alone. The lean-to-fat ratio was more strongly asso-
ciated with walking speed and the risk of self-reported
functional limitation among elderly adults than were lean
or fat mass [29,30]. In addition, the lean-to-fat ratio
appeared to mediate the beneficial effects of leisure time
physical activity on physical functioning [31]. Lean-to-fat
ratio has substantive analytic advantages, because it is
independent of body size and is not collinear with height
(whereas lean mass and height are collinear).
To assess central adiposity (i.e., visceral fat), we measured
sagittal abdominal diameter (SAD). SAD and waist cir-
cumference are both excellent measures of visceral fat as
determined by MRI or CT scanning [32-36]. SAD appears
to be more responsive to weight loss [37]. We chose SAD
over waist circumference for this analysis because it corre-
lates more strongly with pulmonary function (both forced
vital capacity and forced expiratory volume in 1 second
[FEV1]) [38]. Moreover, preliminary analysis indicated
that SAD was related to overall fat mass, whereas waist cir-
cumference was not.
To measure SAD, we used the Holtain Kahn caliper
(Holtain Ltd, U.K.). Subjects were studied in the supine
position. The examiner located the iliac crests, visualized
a line connecting the crests, and marked the center of the
abdomen along this line. The caliper was then slid under
the back and the caliper's upper arm was slid down until
it was 2 cm above the abdominal mark. The caliper was
then leveled using the bubble level. The caliper's upper
arm was then slid down so that it was just touching, but
not compressing, the abdomen. The level position was re-
confirmed and the distance in centimeters was deter-
mined.
Body mass index, as a more general measure of adiposity,
was also determined from height and weight measured at
the research clinic visit (weight in kilograms/height in
meters2). Height was measured by a wall stadiometer in
subjects without shoes; weight was measured by a digital
scale. Body mass index was categorized into 4 groups
using the standard National Heart Lung and Blood Insti-
tute/World Health Organization criteria: underweight (<
18.5 kg/m2), normal weight 18.5–24.9 kg/m2, overweight
(25–29.9 kg/m2), and obese (≥ 30 kg/m2) [39]. Because
there were only 9 subjects in the underweight category
(3%), they were considered with the normal weight group
for analytic purposes.Respiratory Research 2007, 8:7 http://respiratory-research.com/content/8/1/7
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Assessment of physical functional limitation
We assessed functional limitations, which are decrements
in basic physical actions, using a multifaceted evaluation
that combined a survey-based measure (self-reported
functional limitation as described above) and physical
assessment. Submaximal exercise performance was meas-
ured using the Six Minute Walk Test, which was developed
by Guyatt and had been widely used in studies of COPD
[40,41]. We measured submaximal rather than maximal
exercise performance (cardiopulmonary exercise testing)
because most daily activities and work tasks are likely to
require sustained, submaximal exertion rather than high
peak exercise levels. We used a standardized flat, straight
course of 30 meters in accordance with American Thoracic
Society (ATS) Guidelines [42]. Subjects who use home
oxygen or who have a resting oxygen saturation < 90%
wore supplemental oxygen. Every 2 minutes, the techni-
cian spoke standardized encouragement phrases, as rec-
ommended by the ATS guidelines. The primary outcome
was the distance walked in 6 minutes.
Lower extremity function was measured using the vali-
dated Short Physical Performance Battery [43-45]. The
battery included 3 performance measures, which were
scored from 0 to 4 points. The standing balance test asks
subjects to maintain their feet in a side-by-side, semi-tan-
dem stand (heel of one foot next to the big toe of the other
foot), or tandem stand (heel of one foot directly in front
of the other foot) for 10 seconds. The maximum score of
4 is assigned for maintaining the tandem stand for 10 sec-
onds; a low score of 1 is assigned for side-by-side standing
for 10 seconds, with inability to hold a semi-tandem posi-
tion for 10 seconds. A test of walking speed requires sub-
jects to walk 4 meters at their normal pace. Participants
are assigned a score from 1 to 4 based on the quartile of
length of time needed to complete the test. The chair
stand test, which reflects lower extremity extensor muscle
strength, measures the time required for the subject to
stand up and sit down from a chair 5 times with arms
folded across the chest. The chair height is standardized
for all subjects. Scores from 1 to 4 are assigned based on
quartile of length of time to complete the task. A summary
performance score integrates the 3 performance measures,
ranging from 0 to 12. Previous work indicates that the bat-
tery has excellent inter-observer reliability, test-retest reli-
ability, and predictive validity [43-45].
Pulmonary function assessment
To assess respiratory impairment, we conducted spirome-
try according to American Thoracic Society (ATS) Guide-
lines [46,47]. Briefly, subjects were tested in a seated
position with a nose clip in place. After the technician
demonstrated the procedure, subjects performed at least 3
maximal expiratory maneuvers. If reproducibility criteria
are not met (FVC and/or FEV1 variability ≤ 0.2 liters), up
to 8 maneuvers were obtained. We used the EasyOne™
Frontline spirometer (ndd Medical Technologies,
Chelmsford, MA), which meets ATS criteria. To calculate
percent predicted pulmonary function values, we used
predictive equations derived from NHANES III [48].
Because FEV1/FVC ratio is more affected by body size and
composition than FEV1, we used FEV1/FVC in multivariate
analysis to control for pulmonary function impairment
[38,49]. Based on FEV1,FEV1/FVC ratio, and respiratory
symptoms, COPD severity was staged based on NHLBI/
WHO Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) criteria (stage 0 to IV) [6,50].
Statistical analysis
Statistical analysis was conducted using SAS software, ver-
sion 9.1 (SAS Institute, Inc, Cary, NC). We used logistic
regression analysis to elucidate the impact of body com-
position on the risk of self-reported physical functional
limitation. The lean-to-fat ratio was chosen as the primary
body composition variable (as discussed above). We also
examined separate regression models for SAD (an esti-
mate of visceral fat) and BMI (a more general indicator of
adiposity). These variables were not included in the same
models because of their inter-correlation and the concern
for collinearity. To examine potential confounding, 3 sets
of analyses are presented that control for covariates: age;
age, height, and FEV1/FVC; age, height, FEV1/FVC, race
(white, non-Hispanic vs. other), educational attainment,
and smoking history (current smoking and ex-smoking vs.
never smoked). To examine the impact of body composi-
tion on submaximal exercise performance (Six Minute
Walk Test) and lower extremity functioning (Short Physi-
cal Performance Battery), multivariate linear regression
was used in analogous fashion. Because weight is mostly
composed of lean mass and fat mass, it was not included
as a covariate in the regression analysis.
A further series of analyses examined the independent
impact of lean mass, fat mass, and visceral fat (SAD) on
physical functional limitation when considered in the
same regression models. Because lean mass was highly
correlated with height and fat mass, we used the approach
of Sternfeld and colleagues and developed a residual vari-
able for lean mass from its regression on height and fat
mass [29]. The residual variable for lean mass (lean mass-
resid) represents the part of lean mass not accounted for by
height and fat mass (i.e., the correlations between lean
massresid and height, and lean massresid and fat mass are
zero). A residual variable was also developed for SAD
from its regression on fat mass and lean mass (i.e.,
SADresid = that part of SAD not accounted for by fat and
lean mass).
All regression analyses were stratified by sex, because there
was evidence that sex modified the impact of body com-Respiratory Research 2007, 8:7 http://respiratory-research.com/content/8/1/7
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position on the risk of functional limitation in many of
the analyses. This approach is also consistent with the lit-
erature [29,31,51]. To assess the impact of GOLD stage 0
on the results, sensitivity analyses were performed
restricted to subjects with GOLD stages I or greater; the
results were highly consistent with the primary analysis
and are not reported here.
Fat free mass index is sometimes used in studies of body
composition. The fat free mass index strongly correlated
with lean mass (r = 0.91; p < 0.0001). When key analyses
were repeated substituting fat free mass index for lean
mass, the results were highly similar to those based on
lean mass (data not shown).
Results
Subject characteristics
The mean age was 58 (6.2) years and there was a slight
predominance of female subjects (60%) (Table 1). The
majority of subjects were white (64%), with a substantial
proportion of other race-ethnic groups. The majority
(82%) indicated smoking during their lifetime. There was
a diversity of educational attainment.
Table 2 shows pulmonary function and body composi-
tion measurements. The mean FEV1 was 1.71 liters and the
majority of subjects were GOLD stage I or greater. A slight
majority of subjects were obese (54%) based on BMI. A
substantial proportion were overweight (20%) or normal
weight (24%), whereas very few were underweight (3%).
Body composition and functional limitation in COPD
In men, a higher sagittal abdominal diameter was associ-
ated with a greater risk of self-reported functional limita-
tion, but the confidence interval was wide and did not
exclude no effect (OR 1.09 per 1 cm increment; 95% CI
0.99 to 1.21) (Table 3). There was no apparent relation
between lean-fat ratio or BMI and self-reported functional
limitation.
Among women, a higher lean-to-fat ratio was associated
with a lower risk of self-reported functional limitation in
the fully adjusted model (OR 0.45 per 0.50 increment in
lean-to-fat ratio; 95% CI 0.28 to 0.74). Higher sagittal
abdominal diameter and obese body mass index were
also related to a greater risk of functional limitation (OR
1.15 per 1 cm increment; 95% CI 1.07 to 1.23 and OR
3.50 for obese vs. normal BMI; 95% CI 1.53 to 8.01,
respectively).
Body composition was associated with exercise perform-
ance on the Six Minute Walk Test, although the effects
were greater for woman than for men (Table 4). Among
men, a higher lean-to-fat ratio was associated with a
greater distance walked in 6 minutes in the fully adjusted
analysis (mean difference 40 meters per 0.50 ratio incre-
ment; 95% CI 9 to 71 meters). In women, the lean-to-fat
ratio was associated with an even greater distance walked
(mean difference 162 meters per 0.50 increment; 95% CI
97 to 228 meters). Larger sagittal abdominal diameter and
obese BMI were also related to less distance walked in 6
minutes in both sexes (Table 4).
Among men, higher sagittal abdominal diameter was
associated with worse performance on the walking speed
score and summary performance score of the Short Phys-
ical Performance Battery (Table 5). In the female stratum,
lean-to-fat ratio, sagittal abdominal diameter, and obese
BMI were all related to walking speed score, chair stand
scores, and summary performance scores in the expected
directions.
Table 1: Baseline characteristics of 355 adult patients with 
COPD in the FLOW cohort study
Characteristic N (%) or Mean (sd)
Age (years) 58 (6.2)
Sex (female) 212 (60%)
Race (white, non-hispanic) 229 (64%)
Smoking history
Never smoked 63 (18%)
Current smoker 108 (30%)
Ex-smoker 184 (52%)
Educational attainment
High school or less 112 (32%)
Some college 151 (43%)
College or graduate degree 92 (26%)
Table 2: Body composition and pulmonary function among 355 
patients with COPD
Measure Mean (sd) or N (%)
FEV1 (liters) 1.71 (0.77)
FEV1% predicted (%) 57.9 (22.6)
FEV1/FVC 0.60 (0.16)
GOLD Stage
01 0 6  ( 3 0 % )
11 8  ( 5 % )
2 96 (27%)
3 73 (21%)
4 62 (17%)
Height (meters) 1.67 (0.092)
Weight (kg) 86.8 (24.1)
Lean body mass (kg) 49.3 (12.6)
Fat body mass (kg) 34.6 (16.6)
Sagittal abdominal diameter (cm) 24.7 (5.0)
BMI
Underweight (< 18.5 kg/m2)9  ( 3 % )
Normal weight (18.5–24.9 kg/m2) 85 (24%)
Overweight (25.0–29.9 kg/m2) 70 (20%)
Obese (≥ 30 kg/m2)1 9 1  ( 5 4 % )Respiratory Research 2007, 8:7 http://respiratory-research.com/content/8/1/7
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Table 4: Body composition and exercise performance on the Six Minute Walk Test among patients with COPD
Measure of body composition Age adjusted Age, height, FEV1/FVC adjusted Age, height, FEV1/FVC, race, 
education, and smoking adjusted
Mean meters (95% CI) Mean meters (95% CI) Mean meters (95% CI)
MEN (n = 143)
Lean/fat ratio 39 (9 to 69) 42 (11 to 72) 40 (9 to 71)
SAD -29 (-42 to -15) -34 (-47 to -20) -34 (-48 to -19)
BMI
Normal weight Referent Referent Referent
Overweight 27 (-171 to 225) -28 (-225 to 169) -88 (-295 to 120)
Obese -264 (-431 to -97) -263 (-431 to -95) -269 (-451 to -87)
WOMEN (n = 212)
Lean/fat ratio 140 (82 to 199) 159 (96 to 223) 162 (97 to 228)
SAD -34 (-43 to -24) -38 (-48 to -28) -39 (-49 to -28)
BMI
Normal weight Referent Referent Referent
Overweight -42 (-202 to 117) -56 (-217 to 106) -49 (-214 to 115)
Obese -340 (-462 to -218) -392 (-521 to -262) -398 (-531 to -264)
Results are from separate multivariate linear regression of distance in meters walked in 6 minutes regressed on body composition measures plus 
covariates.
Lean/fat ratio = derived from bioelectrical impedance. Results are expressed per 0.50 increment in the ratio.
SAD = sagittal abdominal diameter, an estimate of visceral fat. Results are expressed per 1 cm increment.
BMI = body mass index, an estimate of adiposity; normal weight (18.5 to 24.9 kg/m2) overweight = 25.0 to 29.9 kg/m2, obese = 30.0 kg/m2 or 
greater; only 9/355 (2.5%) of subjects were in underweight category (< 18.5 kg/m2) so these were included in the normal weight group
Table 3: Body composition and the risk of self-reported functional limitation among 355 patients with COPD
Measure of body composition Age adjusted Age, height, FEV1/FVC adjusted Age, height, FEV1/FVC, race, 
education, and smoking adjusted
OR (95% CI) OR (95% CI) OR (95% CI)
MEN (n = 143)
Lean/fat ratio 1.02 (0.87 to 1.20) 0.98 (0.82 to 1.16) 0.99 (0.83 to 1.18)
SAD 1.07 (0.99 to 1316) 1.10 (1.0 to 1.20) 1.09 (0.99 to 1.21)
BMI
Normal weight Referent Referent Referent
Overweight 0.36 (0.10 to 1.27) 0.42 (0.11 to 1.56) 0.46 (0.12 to 1.81)
Obese 0.92 (0.38 to 2.24) 1.16 (0.44 to 3.03) 1.12 (0.39 to 3.20)
WOMEN (n = 212)
Lean/fat ratio 0.49 (0.32 to 0.75) 0.44 (0.27 to 0.70) 0.45 (0.28 to 0.74)
SAD 1.13 (1.06 to 1.21) 1.15 (1.07 to 1.24) 1.15 (1.07 to 1.23)
BMI
Normal weight Referent Referent Referent
Overweight 0.79 (0.28 to 2.24) 0.82 (0.28 to 2.37) 0.74 (0.25 to 2.18)
Obese 3.0 (1.45 to 6.23) 3.77 (1.70 to 8.37) 3.50 (1.53 to 8.01)
Results are from separate multivariate logistic regression of self-reported functional limitation regressed on body composition measures plus 
covariates.
Lean/fat ratio = derived from bioelectrical impedance. Odds ratios are expressed per 0.50 increment in the ratio.
SAD = sagittal abdominal diameter, an estimate of visceral fat. Odds ratios are expressed per 1 cm increment.
BMI = body mass index, an estimate of adiposity; normal weight (18.5 to 24.9 kg/m2) overweight = 25.0 to 29.9 kg/m2, obese = 30.0 kg/m2 or 
greater; only 9/355 (2.5%) of subjects were in underweight category (< 18.5 kg/m2) so these were included in the normal weight group.Respiratory Research 2007, 8:7 http://respiratory-research.com/content/8/1/7
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Relative contribution of lean mass, fat mass, and visceral 
fat to functional limitation
To further elucidate the impact of body composition on
functional limitation, lean mass (residual), fat mass, and
visceral fat (estimated by sagittal abdominal diameter
residual) were included simultaneously in each fully
adjusted multivariate model (see Methods). Among men,
higher fat mass was associated with a decrement in the Six
Minute Walk Test (-13 meters per 1 kg fat mass increment;
95% CI -21 to -5 meters) and was possibly related to a
greater risk of self-reported functional limitations (OR
1.06 per 1 kg increment; 95% CI 0.99 to 1.13) (Table 6).
Higher visceral fat, as estimated by sagittal abdominal
diameter, was also related to poorer walk performance (-
38 meters per 1 cm increment; 95% CI -68 to -7 meters).
Among women, higher fat mass was related to a greater
risk of functional limitations (OR 1.04 per 1 kg increment
in fat mass; 95% CI 1.017 to 1.067), 11 meter decrement
in the distance walked in six minutes (95% CI -15 to -8),
and a poorer SPPB summary performance score (-0.037
points per 1 kg increment; 95% CI -0.053 to -0.020).
Discussion
Body composition abnormality was associated with an
increased risk of functional limitation among patients
with COPD who had a wide spectrum of severity, espe-
cially among women. A lean-to-fat mass ratio was associ-
ated with a decreased risk of self-reported functional
limitation, better submaximal exercise performance (Six
Minute Walk Test), and better lower extremity functioning
(Short Physical Performance Battery), even after control-
ling for pulmonary function impairment and other cov-
ariates. Higher measures of total adiposity (BMI) and
central adiposity (SAD) were also related to greater func-
tional limitation among women. In men, the salutary
effect of lean-to-fat ratio was absent for self-reported func-
tional limitations and lower extremity functioning; it had
a beneficial, albeit attenuated, impact on submaximal
exercise performance. In further analysis, the accumula-
tion of greater fat mass, and not the loss of lean mass, was
most strongly associated with functional limitation
among both sexes. In sum, body composition is an impor-
tant non-pulmonary impairment that modulates the risk
of functional limitation in COPD, even after taking pul-
monary function into account.
Although low fat free mass has been linked with mortality
in COPD, less is known about its impact on functional
limitation, which is a more proximal outcome [16,23].
Depletion of fat free mass has been linked with poorer
submaximal exercise performance and health related
quality of life among patients with very advanced disease
who were participating in pulmonary rehabilitation pro-
grams [15,20]. A more recent study of ambulatory
patients with moderate COPD severity, however, found
no relation between fat free mass and dyspnea or health-
related quality of life, but walking and other related func-
Table 5: The influence of body composition on physical performance among patients with COPD
Measure of body 
composition
Standing balance score Walking speed score Chair stand score Summary performance score
MEN (n = 143)
Lean/fat ratio 0.007 (-0.034 to 0.049) 0.020 (-0.021 to 0.060) 0.038 (-0.05 to 0.13) 0.65 (-0.070 to 0.20)
SAD -0.015 (-0.035 to 0.006) -0.019 (-0.039 to 0.0015)* -0.033 (-0.076 to 0.011) -0.067 (-0.13 to 0.00)
BMI
Normal weight Referent Referent Referent Referent
Overweight 0.060 (-0.22 to 0.34) -0.081 (-0.36 to 0.20) 0.45 (-0.14 to 1.04) 0.43 (-0.48 to 1.35)
Obese -0.13 (-0.38 to 0.11) -0.14 (-0.38 to 0.11) -0.008 (-0.053 to 0.51) -0.28 (-1.08 to 0.52)
WOMEN (n = 212)
Lean/fat ratio 0.070 (-0.023 to 0.16) 0.10 (-0.007 to 0.43)* 0.35 (0.17 to 1.05) 0.52 (0.24 to 0.80)
SAD -0.011(-0.028 to 0.006) -0.033 (-0.052 to -0.14) -0.053 (-0.085 to -0.021) -0.097 (-0.015 to -0.047)
BMI
Normal weight Referent Referent Referent Referent
Overweight -0.003 (-0.25 to 0.24) -0.016 (-0.30 to 0.27) -0.082 (-0.55 to 0.39) -0.10 (-0.84 to 0.64)
Obese -0.029 (-0.23 to 0.17) -0.38 (-0.61 to -0.15) -0.60 (-0.98 to -0.22) -1.00 (-1.61 to -0.40)
All results are mean score (95% CI) from multivariate linear regression controlling for age, height, FEV1/FVC, race, education, and smoking history.
Results are from separate multivariate linear regression of each score regressed on body composition measures plus covariates.
Boldface when p < 0.05 *p = 0.07
Each Short Physical Performance subscale score ranges from 0–4, with higher scores reflecting more favorable performance. Summary performance 
score is sum of each subscale score and ranges from 0–12.
Lean/fat ratio = derived from bioelectrical impedance. Results are expressed per 0.50 increment in the ratio.
SAD = sagittal abdominal diameter, an estimate of visceral fat. Results are expressed per 1 cm increment.
BMI = body mass index, an estimate of adiposity; normal weight (18.5 to 24.9 kg/m2) overweight = 25.0 to 29.9 kg/m2, obese = 30.0 kg/m2 or 
greater; only 9/355 (2.5%) of subjects were in underweight category (< 18.5 kg/m2) so these were included in the normal weight groupRespiratory Research 2007, 8:7 http://respiratory-research.com/content/8/1/7
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tional limitations were not evaluated [24]. Our study
demonstrated that body composition has an important
impact on functional limitation among persons with ear-
lier stage disease, when prevention may still be possible.
Compared to earlier studies, we were also able to parse
out the independent effects of lean mass and fat mass.
Our results suggest that COPD may accelerate the impact
of body composition that occurs with normal ageing.
Among elderly adults who were an average of 11 years
older than our cohort, the lean-to-fat ratio was an impor-
tant determinant of functional limitation, especially
among women [29-31]. Greater fat mass was the most
important predictor of more functional limitation; lean
mass was only predictive in relation to fat mass. Other
population-based studies of the elderly have also sug-
gested that fat mass is the most important influence on
functional limitation [52-54]. Overall, it appears that the
increase of fat mass, and not simply the loss of lean mass,
is an important precursor for the development of func-
tional limitation and that this process is occurring at an
earlier age in COPD than in the general population. This
differs from the traditional view, which posits that lean
mass depletion is the most important determinant in
COPD [55].
The present study is subject to several limitations.
Although the inclusion criteria require health care utiliza-
tion for COPD, misclassification of asthma could affect
the study results. Our COPD definition required concom-
itant treatment with COPD medications to increase the
specificity of the definition. The observed lifetime smok-
ing prevalence was similar to that in other population-
based epidemiologic studies of COPD, supporting the
diagnosis of COPD over asthma [1,56]. We also previ-
ously demonstrated the validity of our approach using
medical record review [27]. Moreover, we demonstrated
that all patients met the GOLD criteria for COPD. None-
theless, we cannot exclude the possibility that some sub-
jects, especially GOLD stage 0, have conditions other than
COPD. For the present analysis, we would expect such
misclassification to have a conservative effect (i.e., reduc-
ing the impact of body composition on functional limita-
tion).
Because our focus was on disability prevention, we inten-
tionally sampled younger adults with COPD. Therefore,
these results may underestimate the impact of body com-
position among older patients with COPD In addition,
Kaiser Permanente members, because they have health
care access, may also be different than the general popula-
tion of adults with COPD. Mitigating these limitations,
the sociodemographic characteristics of Northern Califor-
nia Kaiser Permanente members are similar to those of the
regional population, with some under-representation of
income extremes [25,26]. Moreover, selection bias could
have been introduced by non-participation in the study,
but the demographic characteristics of those who did and
did not participate are similar (data not shown). Our sub-
jects also had a low prevalence of underweight and a high
prevalence of obesity, which likely reflects the broad range
of disease severity; this could reduce generalizability to
populations of end-stage COPD patients who often have
more underweight persons.
We did not perform DEXA in this cohort, which is the best
clinically available measure of lean and fat mass. We did,
however, use regression equations to estimate fat and lean
mass that were recently developed and validated for sub-
jects living within the catchment area of the study [29].
There are, however, alternative equations for estimating
body composition [15]. Another limitation was inade-
quate statistical power to evaluate the impact of lean and
fat mass within BMI categories. In addition, we did not
Table 6: Independent influence of lean and fat mass on functional limitation in COPD
Measure of body composition Self-reported functional limitation Six Minute Walk Test SPPB Summary Performance Score
OR (95% CI) Mean (95% CI) Mean (95% CI)
MEN (n = 143)
Lean massresid 1.0 (0.89 to 1.12) 5 (-10 to 20) 0.018 (-0.05 to 0.09)
Fat mass 1.06 (0.99 to 1.13)* -13 (-21 to -5) -0.025 (-0.062 to 0.013)
SADresid 0.95 (0.76 to 1.19) -38 (-68 to -7) -0.097 (-0.24 to 0.043)
WOMEN (n = 212)
Lean massresid 1.005 (0.91 to 1.12) -14 (-31 to 3) 0.034 (-0.044 to 0.11)
Fat mass 1.04 (1.017 to 1.067) -11 (-15 to -8) -0.037 (-0.053 to -0.020)
SADresid 1.09 (0.94 to 1.26) -16 (-39 to 7) -0.012 (-0.12 to 0.097)
Logistic or linear multivariate regression including variables shown plus age, FEV1/FVC, height, race, education, and smoking. *p = 0.077
Results are for 1 kg increment in lean or fat mass OR per 1 cm increment in SAD
Lean massresid = residual variable for lean mass removing the contribution of fat mass and height;
SADresid = residual variable for sagittal abdominal diameter removing the contribution of lean mass and fat mass (see Methods)Respiratory Research 2007, 8:7 http://respiratory-research.com/content/8/1/7
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have a control group for this analysis so the relative
impact of body composition on patients with COPD com-
pared to the general population could not be evaluated.
Conclusion
Pulmonary function impairment, although it is the most
salient abnormality in COPD, cannot explain why some
patients develop functional limitations and disability and
others do not. A lower lean-to-fat ratio is associated with
greater functional limitation, especially among women.
Moreover, higher fat mass has a particularly negative
impact on function. Consequently, body composition
abnormalities may represent an important area for screen-
ing and preventive intervention in COPD. Further studies
are needed to evaluate the efficacy of these interventions.
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Appendix
Assessment of self-reported functional limitations
The next questions ask about difficulties that you might
have with common activities. For the next items, please
tell me what level of difficulty you have had during the
past month: a lot of difficulty, some difficulty, a little dif-
ficulty, or no difficulty.
During the past month, how much difficulty have you
had....
In pushing objects, like a living room chair?
In stooping, crouching, or kneeling?
In getting up from a stooping, crouching, or kneeling
position?
In lifting or carrying items under 10 pounds, like a bag of
potatoes?
In lifting or carrying items over 10 pounds, like a bag of
groceries?
In standing in place for 15 minutes or longer?
In sitting for long periods, say 1 hour?
In standing up after sitting in a chair?
In walking alone up and down a flight of stairs?
In walking two or three neighborhood blocks?
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